Hematopoietic stem cell therapy for type 1 diabetes: Induction of tolerance and islet cell neogenesis

Richard K Burt*, Yu Oyama, Ann Traynor, Norma S. Kenyon

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

32 Scopus citations


Diabetes is a chronic disease with significant morbidity and mortality. Pancreas or islet cell transplantation is limited by a shortage of donors and chronic immune suppression to prevent allograft rejection. Consequently, interest exists in islet cell neogenesis from embryonic or mesenchymal stem cell as a possible cure for diabetes. However, unless tolerance to islet cells is re-established, diabetes treated by islet cell transplantation would remain a chronic disease secondary to immune suppression related morbidity. If islet cell tolerance could be re-induced, a major clinical hurdle to curing diabetes by islet cell neogenesis may be overcome. Recent studies suggest that adult hematopoietic stem cells (HSC) can reintroduce tolerance to auto-antigens. It is possible that HSC may also be able to switch lineage and, therefore, be a convenient source of stem cells for both inducing tolerance and islet cell regeneration.

Original languageEnglish (US)
Pages (from-to)133-138
Number of pages6
JournalAutoimmunity Reviews
Issue number3
StatePublished - May 2002


  • Islet cell neogenesis
  • Stem cell therapy
  • Type 1 diabetes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Hematopoietic stem cell therapy for type 1 diabetes: Induction of tolerance and islet cell neogenesis'. Together they form a unique fingerprint.

Cite this